Journal Article
. 2014 Nov;148(3).
doi: 10.1007/s10549-014-3192-3.

Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study

D Balmativola 1 C Marchiò  M Maule  L Chiusa  L Annaratone  F Maletta  F Montemurro  J Kulka  P Figueiredo  Z Varga  I Liepniece-Karele  G Cserni  E Arkoumani  I Amendoeira  G Callagy  A Reiner-Concin  A Cordoba  S Bianchi  T Decker  D Gläser  C Focke  P van Diest  D Grabau  E Lips  J Wesseling  R Arisio  E Medico  C Wells  A Sapino  
  • PMID: 25395316
  •     44 References
  •     13 citations


To identify markers of non-response to neoadjuvant chemotherapy (NAC) that could be used in the adjuvant setting. Sixteen pathologists of the European Working Group for Breast Screening Pathology reviewed the core biopsies of breast cancers treated with NAC and recorded the clinico-pathological findings (histological type and grade; estrogen, progesterone receptors, and HER2 status; Ki67; mitotic count; tumor-infiltrating lymphocytes; necrosis) and data regarding the pathological response in corresponding surgical resection specimens. Analyses were carried out in a cohort of 490 cases by comparing the groups of patients showing pathological complete response (pCR) and partial response (pPR) with the group of non-responders (pathological non-response: pNR). Among other parameters, the lobular histotype and the absence of inflammation were significantly more common in pNR (p < 0.001). By ROC curve analyses, cut-off values of 9 mitosis/2 mm(2) and 18% of Ki67-positive cells best discriminated the pNR and pCR + pPR categories (p = 0.018 and < 0.001, respectively). By multivariable analysis, only the cut-off value of 9 mitosis discriminated the different response categories (p = 0.036) in the entire cohort. In the Luminal B/HER2- subgroup, a mitotic count <9, although not statistically significant, showed an OR of 2.7 of pNR. A lobular histotype and the absence of inflammation were independent predictors of pNR (p = 0.024 and <0.001, respectively). Classical morphological parameters, such as lobular histotype and inflammation, confirmed their predictive value in response to NAC, particularly in the Luminal B/HER2- subgroup, which is a challenging breast cancer subtype from a therapeutic point of view. Mitotic count could represent an additional marker but has a poor positive predictive value.

The effect of random measurement error on receiver operating characteristic (ROC) curves.
D Faraggi.
Stat Med, 2000 Jan 07; 19(1). PMID: 10623913
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.
R Salgado, C Denkert, +30 authors, International TILs Working Group 2014.
Ann Oncol, 2014 Sep 13; 26(2). PMID: 25214542    Free PMC article.
Highly Cited.
Selecting the neoadjuvant treatment by molecular subtype: how to maximize the benefit?
Gunter von Minckwitz, Caterina Fontanella.
Breast, 2013 Oct 01; 22 Suppl 2. PMID: 24074777
Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer.
Aleix Prat, Maggie Chon U Cheang, +8 authors, Charles M Perou.
J Clin Oncol, 2012 Dec 13; 31(2). PMID: 23233704    Free PMC article.
Highly Cited.
Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer.
Michael J Hassett, Samuel M Silver, +12 authors, Jane C Weeks.
J Clin Oncol, 2012 May 16; 30(18). PMID: 22585699    Free PMC article.
Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review.
Elisabeth Luporsi, Fabrice André, +22 authors, Jean-Pierre Bellocq.
Breast Cancer Res Treat, 2011 Nov 04; 132(3). PMID: 22048814    Free PMC article.
Highly Cited. Review.
The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer.
Marieke E Straver, Annuska M Glas, +7 authors, Sjoerd Rodenhuis.
Breast Cancer Res Treat, 2009 Feb 14; 119(3). PMID: 19214742
Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment.
Peter A Fasching, Katharina Heusinger, +14 authors, David L Wachter.
BMC Cancer, 2011 Nov 16; 11. PMID: 22081974    Free PMC article.
Highly Cited.
High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer.
Carmen Criscitiello, Davide Disalvatore, +12 authors, Giuseppe Curigliano.
Breast, 2013 Dec 10; 23(1). PMID: 24314620
Supervised risk predictor of breast cancer based on intrinsic subtypes.
Joel S Parker, Michael Mullins, +17 authors, Philip S Bernard.
J Clin Oncol, 2009 Feb 11; 27(8). PMID: 19204204    Free PMC article.
Highly Cited.
Mitotic figure counts are significantly overestimated in resection specimens of invasive breast carcinomas.
Hans-Anton Lehr, Candice Rochat, +11 authors, Stephan C Schaefer.
Mod Pathol, 2012 Oct 09; 26(3). PMID: 23041831
Measuring the effectiveness of diagnostic markers in the presence of measurement error through the use of ROC curves.
B Reiser.
Stat Med, 2000 Aug 10; 19(16). PMID: 10931515
Adjuvant chemotherapy: which patient? What regimen?
Natalie Turner, Laura Biganzoli, +6 authors, Angelo Di Leo.
Am Soc Clin Oncol Educ Book, 2013 May 30;. PMID: 23714442
In patients younger than age 55 years with lymph node-negative breast cancer, proliferation by mitotic activity index is prognostically superior to adjuvant!
Tone Hoel Lende, Emiel A M Janssen, +5 authors, Jan P A Baak.
J Clin Oncol, 2010 Dec 30; 29(7). PMID: 21189388
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.
A Goldhirsch, E P Winer, +5 authors, Panel members.
Ann Oncol, 2013 Aug 07; 24(9). PMID: 23917950    Free PMC article.
Highly Cited.
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.
Mitch Dowsett, Torsten O Nielsen, +19 authors, International Ki-67 in Breast Cancer Working Group.
J Natl Cancer Inst, 2011 Oct 01; 103(22). PMID: 21960707    Free PMC article.
Highly Cited.
The pathologic complete response open question in primary therapy.
Caterina Marchiò, Anna Sapino.
J Natl Cancer Inst Monogr, 2011 Nov 02; 2011(43). PMID: 22043049
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up.
C W Elston, I O Ellis.
Histopathology, 1991 Nov 01; 19(5). PMID: 1757079
Highly Cited.
Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy.
Anne Vincent-Salomon, Alexandra Rousseau, +10 authors, Breast Cancer Study Group.
Eur J Cancer, 2004 Jun 16; 40(10). PMID: 15196533
An international Ki67 reproducibility study.
Mei-Yin C Polley, Samuel C Y Leung, +16 authors, International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group.
J Natl Cancer Inst, 2013 Nov 10; 105(24). PMID: 24203987    Free PMC article.
Highly Cited.
Developments in Ki67 and other biomarkers for treatment decision making in breast cancer.
A Sheri, M Dowsett.
Ann Oncol, 2012 Sep 26; 23 Suppl 10. PMID: 22987966
Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial.
C Denkert, S Loibl, +17 authors, G von Minckwitz.
Ann Oncol, 2013 Aug 24; 24(11). PMID: 23970015
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.
Luca Gianni, Milvia Zambetti, +14 authors, Steven Shak.
J Clin Oncol, 2005 Sep 08; 23(29). PMID: 16145055
Highly Cited.
Tumor-infiltrating follicular helper T cells: The new kids on the block.
Chunyan Gu-Trantien, Karen Willard-Gallo.
Oncoimmunology, 2013 Nov 19; 2(10). PMID: 24244900    Free PMC article.
Laboratory handling and histology reporting of breast specimens from patients who have received neoadjuvant chemotherapy.
S E Pinder, E Provenzano, H Earl, I O Ellis.
Histopathology, 2007 Apr 24; 50(4). PMID: 17448015
Comparison of the prognostic significance of Chevallier and Sataloff's pathologic classifications after neoadjuvant chemotherapy of operable breast cancer.
Frederique Penault-Llorca, Catherine Abrial, +7 authors, Philippe Chollet.
Hum Pathol, 2008 Jun 13; 39(8). PMID: 18547616
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes.
Massimo Cristofanilli, Ana Gonzalez-Angulo, +9 authors, Gabriel N Hortobagyi.
J Clin Oncol, 2004 Dec 31; 23(1). PMID: 15625359
Response to neoadjuvant chemotherapy in ductal compared to lobular carcinoma of the breast: a meta-analysis of published trials including 1,764 lobular breast cancer.
Fausto Petrelli, Sandro Barni.
Breast Cancer Res Treat, 2013 Nov 02; 142(2). PMID: 24177758
Systematic Review.
REporting recommendations for tumor MARKer prognostic studies (REMARK).
Lisa M McShane, Douglas G Altman, +4 authors, Statistics Subcommittee of NCI-EORTC Working Group on Cancer Diagnostics.
Breast Cancer Res Treat, 2006 Aug 26; 100(2). PMID: 16932852
Highly Cited.
Immunohistochemical Ki67 labeling index has similar proliferation predictive power to various gene signatures in breast cancer.
Naoki Niikura, Takayuki Iwamoto, +9 authors, Yutaka Tokuda.
Cancer Sci, 2012 Apr 28; 103(8). PMID: 22537114    Free PMC article.
Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer: is it equally useful across tumor subtypes?
Aiko Sueta, Yutaka Yamamoto, +5 authors, Hirotaka Iwase.
Surgery, 2014 Mar 04; 155(5). PMID: 24582496
The proliferation rate paradox in antimitotic chemotherapy.
Timothy J Mitchison.
Mol Biol Cell, 2012 Jan 03; 23(1). PMID: 22210845    Free PMC article.
Highly Cited.
Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.
Carsten Denkert, Sibylle Loibl, +14 authors, Gunter von Minckwitz.
J Clin Oncol, 2009 Nov 18; 28(1). PMID: 19917869
Highly Cited.
Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma.
V F Cocquyt, P N Blondeel, +7 authors, S J P Van Belle.
Eur J Surg Oncol, 2003 Apr 25; 29(4). PMID: 12711290
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
Maggie C U Cheang, Stephen K Chia, +10 authors, Torsten O Nielsen.
J Natl Cancer Inst, 2009 May 14; 101(10). PMID: 19436038    Free PMC article.
Highly Cited.
Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma.
Sibylle Loibl, Cristina Volz, +19 authors, Michael Untch.
Breast Cancer Res Treat, 2014 Feb 08; 144(1). PMID: 24504379
Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy.
Frédérique Penault-Llorca, Catherine Abrial, +7 authors, Xavier Durando.
Oncologist, 2008 Dec 19; 13(12). PMID: 19091781
CD4⁺ follicular helper T cell infiltration predicts breast cancer survival.
Chunyan Gu-Trantien, Sherene Loi, +21 authors, Karen Willard-Gallo.
J Clin Invest, 2013 Jun 20; 123(7). PMID: 23778140    Free PMC article.
Highly Cited.
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.
S Loi, S Michiels, +13 authors, C Sotiriou.
Ann Oncol, 2014 Mar 13; 25(8). PMID: 24608200
Highly Cited.
Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas.
Y Delpech, C Coutant, +7 authors, L Pusztai.
Br J Cancer, 2013 Jan 10; 108(2). PMID: 23299541    Free PMC article.
Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.
Sherene Loi, Nicolas Sirtaine, +13 authors, Christos Sotiriou.
J Clin Oncol, 2013 Jan 24; 31(7). PMID: 23341518
Highly Cited.
The prognostic value of mitotic activity index (MAI), phosphohistone H3 (PPH3), cyclin B1, cyclin A, and Ki67, alone and in combinations, in node-negative premenopausal breast cancer.
Marie Klintman, Carina Strand, +11 authors, Mårten Fernö.
PLoS One, 2013 Dec 11; 8(12). PMID: 24324728    Free PMC article.
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Kathy S Albain, William E Barlow, +20 authors, Breast Cancer Intergroup of North America.
Lancet Oncol, 2009 Dec 17; 11(1). PMID: 20005174    Free PMC article.
Highly Cited.
International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013).
Vito Amoroso, Daniele Generali, +30 authors, Alberto Bottini.
J Natl Cancer Inst Monogr, 2015 Jun 13; 2015(51). PMID: 26063896    Free PMC article.
High Expression of Pyruvate Kinase M2 is Associated with Chemosensitivity to Epirubicin and 5-Fluorouracil in Breast Cancer.
Yang Lin, Feng Lv, +5 authors, Li Fu.
J Cancer, 2015 Oct 31; 6(11). PMID: 26516361    Free PMC article.
Tumor slice culture system to assess drug response of primary breast cancer.
Kishan A T Naipal, Nicole S Verkaik, +7 authors, Dik C van Gent.
BMC Cancer, 2016 Feb 11; 16. PMID: 26860465    Free PMC article.
Expression of cell cycle markers is predictive of the response to primary systemic therapy of locally advanced breast cancer.
Tímea Tőkés, Anna-Mária Tőkés, +5 authors, Magdolna Dank.
Virchows Arch, 2016 Mar 31; 468(6). PMID: 27026269
Neoadjuvant chemotherapy in breast cancers.
Shahla Masood.
Womens Health (Lond), 2016 Nov 26; 12(5). PMID: 27885165    Free PMC article.
Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy.
Balázs Ács, Veronika Zámbó, +9 authors, Anna-Mária Tőkés.
Diagn Pathol, 2017 Feb 23; 12(1). PMID: 28222768    Free PMC article.
Neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study.
Nobuaki Sato, Norikazu Masuda, +9 authors, Masakazu Toi.
Cancer Med, 2018 Jun 16;. PMID: 29905023    Free PMC article.
The Dilemma of HER2 Double-equivocal Breast Carcinomas: Genomic Profiling and Implications for Treatment.
Caterina Marchiò, Patrizia Dell'Orto, +23 authors, Anna Sapino.
Am J Surg Pathol, 2018 Jul 06; 42(9). PMID: 29975246    Free PMC article.
Predicting the response to neoadjuvant therapy for early-stage breast cancer: tumor-, blood-, and imaging-related biomarkers.
Wenyong Tan, Ming Yang, +2 authors, Weixi Shen.
Cancer Manag Res, 2018 Oct 24; 10. PMID: 30349367    Free PMC article.
Circulating Cell-Free DNA and Colorectal Cancer: A Systematic Review.
Veronika Vymetalkova, Klara Cervena, Linda Bartu, Pavel Vodicka.
Int J Mol Sci, 2018 Oct 31; 19(11). PMID: 30373199    Free PMC article.
Systematic Review.
Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer.
Paul Gass, Michael P Lux, +12 authors, Marius Wunderle.
BMC Cancer, 2018 Oct 31; 18(1). PMID: 30373556    Free PMC article.
Cytoplasmic Cyclin E Expression Predicts for Response to Neoadjuvant Chemotherapy in Breast Cancer.
Cansu Karakas, Ashleigh M Francis, +10 authors, Kelly K Hunt.
Ann Surg, 2019 Aug 23;. PMID: 31436549    Free PMC article.
Prognostic and Clinicopathological Correlations of Cell Cycle Marker Expressions before and after the Primary Systemic Therapy of Breast Cancer.
Tímea Tőkés, Anna-Mária Tőkés, +6 authors, Magdolna Dank.
Pathol Oncol Res, 2019 Aug 26; 26(3). PMID: 31446607    Free PMC article.